Metabolic disorders
Amgen remains confident in its obesity asset MariTide, for which it has launched a broad Phase III program.
Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO Albert Bourla was limited in what he could say. But he said Pfizer was the best fit for Metsera.
Both companies have submitted revised bids, with Novo’s coming in $1.9 billion higher than Pfizer’s.
Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs to pay for the next generation of obesity medicines to come after that.
Mounjaro and Zepbound contributed more than $10 billion to the $11.98 billion in sales Lilly recorded for key products in the third quarter, despite price decreases for the GLP-1 medicines.
Pfizer called Novo’s offer “reckless and unprecedented,” in a statement issued Thursday morning.
The reprioritization initiative extends Aldeyra’s cash runway into the second half of 2027.
Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone.
Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN-601.
PRESS RELEASES